Results 131 to 140 of about 283,504 (300)

Economic Evaluation of Positron Emission Tomography (PET) in Non Small Cell Lung Cancer (NSCLC), CHERE Working Paper 2007/6 [PDF]

open access: yes
Background: There are several perceived benefits from introducing positron emission tomography (PET) scanning into the staging of non small lung cancer (NSCLC).
Alex Bird   +2 more
core  

Electronic Health Records to Test Multimorbidity Influences to Plasma Biomarker Interpretation for Alzheimer's Disease

open access: yesAnnals of Neurology, EarlyView.
Objective Plasma biomarkers of Alzheimer's disease (AD) pathology are frequently tested in specialized research settings, which limits the generalizability of findings. Using electronic health records and banked plasma, we evaluated plasma biomarkers—phosphorylated tau 217 (p‐tau217), β‐amyloid 1–42/1–40 (Aβ42/Aβ40) and p‐tau217/Aβ42—in a real‐world ...
Katheryn A.Q. Cousins   +12 more
wiley   +1 more source

Toward Harmonizing Quantification of Dopamine Neuron Imaging Biomarkers in Parkinson's Disease: The Centamine Scale

open access: yesAnnals of Neurology, EarlyView.
Objective Dopaminergic imaging is a key biomarker for both the investigation of the biology of Parkinson's disease and related synucleinopathies and the evaluation of potential therapies in clinical trials. This work presents a harmonized approach for quantifying dopaminergic molecular imaging tracers, such as [123I]ioflupane (dopamine transporter scan
Zhen Fan   +174 more
wiley   +1 more source

Revisiting Incomplete Tissue‐Level Reperfusion Following Successful Thrombectomy for Acute Ischemic Stroke

open access: yesAnnals of Neurology, EarlyView.
Among patients with acute ischemic stroke achieving successful large vessel recanalization (defined as expanded Thrombolysis in Cerebral Infarction [eTICI ≥2b]), incomplete tissue‐level reperfusion, distinct from visually identifiable distal occlusion on digital‐subtraction angiography, remains a significant challenge.
Yue Qiao   +4 more
wiley   +1 more source

When Does Alzheimer's Disease Start? Plasma Aβ42/40 Assays Show Steep Changes at Aβ‐PET Centiloid 15, Mean Age of 66 Years

open access: yesAnnals of Neurology, EarlyView.
Objective Sporadic late‐onset Alzheimer's disease (AD) is characterized by a long pre‐clinical phase where amyloid‐beta (Aβ) and tau begin to accumulate in the brain. The primary objective was to determine the age at which AD starts by finding the average population age when both positron emission tomography (PET) Aβ (Aβ‐PET) and plasma Aβ42/40 become ...
Rodrigo Cánovas   +29 more
wiley   +1 more source

Tau Pathology in Alzheimer's Disease Uniquely Affects Sulcal Depths

open access: yesAnnals of Neurology, EarlyView.
Objective Though it is widely known that tau deposition affects brain structure, the precise localization of these effects is poorly understood, especially in relation to gyral and sulcal anatomy. We investigated whether tau pathology in Alzheimer's disease (AD) preferentially affects sulci, and particularly sulcal depths.
Samira A. Maboudian   +10 more
wiley   +1 more source

Individualized Atrophy‐Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed‐Effects Modeling

open access: yesAnnals of Neurology, EarlyView.
Objective Age of symptom onset is highly variable in familial frontotemporal lobar degeneration (f‐FTLD). Accurate prediction of onset would inform clinical management and trial enrollment. Prior studies indicate that individualized maps of brain atrophy can predict conversion to dementia in f‐FTLD.
Shubir Dutt   +82 more
wiley   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

open access: yesArthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Home - About - Disclaimer - Privacy